PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026

"The Report PharmaPoint: Healthcare-Associated Gram-Negative Infections - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Healthcare-Associated Gram-Negative Infections Market

Healthcare-associated infections (HAIs) are a major threat to patient safety, and place a substantial economic burden on healthcare systems. HAIs occur in hospitalized patients, and are not present at the time of admission. Acute care hospitals are the primary settings for contracting HAIs, with a high concentration occurring within non-nursery wards and intensive care units (ICUs).The most common types of HAIs are related to the use of invasive devices or surgical procedures, and fall into the following infection site categories: catheter-associated urinary tract infection (CAUTI), central line-associated bloodstream infection (CLABSI), hospital-associated pneumonia/ventilator-associated pneumonia (HAP/VAP), and surgical site infection (SSI).

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1362814

The pharmaceutical industrys battle against Gram-negative bacteria requires ongoing development and novel, innovative approaches for the development of new antibiotics as well as non-antibiotic based approaches. Due to the lack of novel scaffolds being developed over the last few decades and limited investments into antibiotic R&D during this century, the prevalence of resistant Gram-negative bacteria, especially in the hospital setting, has increased significantly; antibiotic resistance is now considered a major threat to the life expectancy of current future generations, including in developed countries. Consequently, industry and governments have recently ramped up their involvement in this space, and several promising antibiotics are now in the late-stage development.

View Report @ https://www.marketresearchreports.biz/reports/1362814/pharmapoint-healthcare-associated-gram-negative-infections-market-research-reports

Scope

- Overview of HAIs caused by Gram-negative bacteria, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline market revenue from 2016-2026 for HAIs caused by Gram-negative bacteria. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global therapeutics market for HAIs caused by Gram-negative bacteria. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1362814

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global therapeutics market for HAIs caused by Gram-negative bacteria.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the therapeutics market for HAIs caused by Gram-negative bacteria in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11
2 Executive Summary 13
2.1 Launch of Patented Antibiotics Will Drive Solid Growth Over the Forecast Period 14
2.2 Pipeline Portfolios Target Highly Resistant Bacteria in Strong Collaborations With Governments 17
2.3 Drug Portfolios Address Some Unmet Needs, but Some Opportunities Remain With New Foreseeable Challenges 18
2.4 Companies Must Quickly Adapt to Exploit Opportunities in an Evolving Marketplace 19
2.5 Novel Antibiotics Are Poised to Drive Growth Despite Entering a Highly Genericized Marketplace 20
2.6 What Do Physicians Think? 22
3 Introduction 26
3.1 Catalyst 26
3.2 Related Reports 27
3.3 Upcoming Related Reports 27
4 Disease Overview 28
4.1 Infection Scope and Coverage Overview 28
4.2 Etiology and Pathophysiology 28
4.2.1 Etiology 28
4.2.2 Pathophysiology 37
4.3 Symptoms 48
4.4 Prognosis 49
5 Epidemiology 51
5.1 Disease Background 51
5.2 Risk Factors and Comorbidities 52
5.3 Global and Historical Trends 53
5.3.1 US 53
5.3.2 5EU 54
5.3.3 Japan 54
5.4 Forecast Methodology 55
5.4.1 Sources 56
5.4.2 Forecast Assumptions and Methods 59
5.5 Epidemiological Forecast for Suspected HAIs and Gram-Negative HAIs (2016-2026) 68
5.5.1 Suspected Incident Cases of Select HAIs 68
5.5.2 Diagnosed Incident Cases of Select Gram-Negative HAIs 69
5.5.3 Suspected Incident Cases of Select HAIs by Infection Site 70
5.5.4 Diagnosed Incident Cases of Select Gram-Negative HAIs by Infection Site 71
5.5.5 Diagnosed Incident Cases of Select Gram-Negative HAIs by Causative Agent 72
5.6 Discussion 76
5.6.1 Epidemiological Forecast Insight 76
5.6.2 Limitations of the Analysis 78
5.6.3 Strengths of the Analysis 78
6 Disease Management 80
6.1 Diagnosis and Treatment Overview 80
6.1.1 Diagnosis 80
6.1.2 Treatment Guidelines 82
6.1.3 Clinical Practice 84
6.1.4 Antibiotic Stewardship Programs 85
6.1.5 Off-Label Use of Antibiotics 87
6.2 US. 87
6.3 5EU. 90
6.4 Japan. 92
7 Competitive Assessment 94
7.1 Overview 94
7.2 Product Profiles - Beta-Lactam Antibiotics 100
7.2.1 Overview 100
7.2.2 Fixed Dose Beta-Lactam Combination Drugs 101
7.2.3 Monobactam antibiotics 119
7.2.4 Carbapenems 122
7.2.5 Cephalosporins 133
7.3 Product Profiles - Fluoroquinolones 135
7.3.1 Overview 135
7.3.2 Levofloxacin (numerous brand names) 137
7.3.3 Ciprofloxacin (numerous brand names) 140
7.3.4 Moxifloxacin (numerous brand names) 143
7.4 Product Profiles - Polymixins 145
7.4.1 Overview 145
7.4.2 Forecast 147
7.5 Product Profiles - Aminoglycosides 147
7.5.1 Overview 147
7.5.2 Amikacin (numerous brand names) 150
7.5.3 Gentamicin (numerous brand names) 153
7.5.4 Tobramycin (numerous brand names) 156
7.6 Product Profiles - Tetracyclines 157
7.6.1 Tygacil (tigecycline) 157
7.7 Product Profiles - Other Antibiotics 161

Buy Now @ https://www.researchmoz.com/checkout?rep_id=1362814&licType=S

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.